Proteomic analysis in patients with dedifferentiated liposarcoma (DDLPS) in a phase Ia/Ib study of the MDM2–p53 antagonist brigimadlin.
Jaimes Y, LoRusso P, Sturm G, Gounder M, Yamamoto N, Somaiah N, Lugowska I, Moreno V, Peltzer A, Teufel M, Jayadeva G, Schöffski P. Proteomic analysis in patients with dedifferentiated liposarcoma (DDLPS) in a phase Ia/Ib study of the MDM2–p53 antagonist brigimadlin. Journal Of Clinical Oncology 2024, 42: 11541-11541. DOI: 10.1200/jco.2024.42.16_suppl.11541.Peer-Reviewed Original ResearchPhase Ia/Ib studyDedifferentiated liposarcomaDDLPS samplesTranscriptional regulation of target genesPlasma samplesPAI-1Angiopoietin-1Cycle 3 day 1Neutrophil gelatinase-associated lipocalin levelsC-C motif chemokine 5Regulation of target genesTumor suppressor p53Cox hazard ratio modelAdvanced solid tumorsProteomic analysis of plasma samplesRestore p53 activityAXL receptor tyrosine kinaseElevated GDF-15MDM2-p53 antagonistsReceptor tyrosine kinasesP53 targetsTranscriptional regulationHazard ratio modelMyelosuppression eventsP53 activation